|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Poly dimethylsiloxane/carbon nanofiber nanocomposites: fabrication and characterization of electrical and thermal properties显示文摘This article presents the fabrication and characterization of poly dimethylsiloxane/carbon nanofiber(CNF)-based nanocomposites.Although silica and carbon nanoparticles have been traditionally used to reinforce mechanical properties in PDMS matrix nanocom-posites,this article focuses on understanding their impacts on electrical and thermal properties.By adjusting both the silica and CNF concentrations,12 different nanocomposite formulations were studied,and the thermal and electrical properties of these materials were experimentally characterized.The developed nano-composites were prepared using a solvent-assisted method pro-viding uniform dispersion of the CNFs in the polymer matrix.Scanning electron microscopy was employed to determine the dispersion of the CNFs at different length scales.The thermal properties,such as thermal stability and thermal diffusivity,of the developed nanocomposites were studied using thermogravi-metirc and laser flash techniques.Furthermore,the electrical volume conductivity of each type of nanocomposite was tested using the four-probe method to eliminate the effects of contact electrical resistance during measurement.Experimental results showed that both CNFs and silica were able to impact on the overall properties of the synthesized PDMS/CNF nanocomposites.The developed nanocomposites have the potential to be applied to the development of new load sensors in the future. | Shoieb Chowdhury Mark Olima Yingtao Liu Mrinal Saha James Bergman Thomas Robison | 2016 | International Journal of Smart and Nano Materials2016，7，4： | 1 |
| 2 | The role of intravenous fluorescein in the detection of colon ischemia during aortic reconstruction显示文摘 | R. Thomas Bergman MD Peter Gloviczki MD Timothy J. Welch MD James M. Naessens MPH Thomas C. Bower MD John W. Hallett MD Peter C. Pairolero MD Kenneth J. Cherry MD | 1992 | Annals of Vascular Surgery1992，，1： | 1 |
| 3 | Clinical Benefit of Preserving Residual Renal Function in Dialysis Patients: An Update for Clinicians显示文摘 | Zachary Z. Brener Peter Kotanko Stephan Thijssen James F. Winchester Michael Bergman | 2010 | The American Journal of the Medical Sciences2010，，5： | 1 |
| 4 | Management of recurrent and persistent metastatic lymph nodes in well‐differentiated thyroid cancer: A multifactorial decision‐making guide for the thyroid cancer care collaborative显示文摘 | Mark L. Urken Mira Milas Gregory W. Randolph Ralph Tufano Donald Bergman Victor Bernet Elise M. Brett James D. Brierley Rhoda Cobin Gerard Doherty Joshua Klopper Stephanie Lee Josef Machac Jeffrey I. Mechanick Lisa A. Orloff Douglas Ross Robert C. Smallri | 2015 | Head Neck2015，，4： | 1 |
| 5 | The role of intravenous fluorescein in the detection of colon ischemia during aortic reconstruction显示文摘 | R. Thomas Bergman MD Peter Gloviczki MD Timothy J. Welch MD James M. Naessens MPH Thomas C. Bower MD John W. Hallett MD Peter C. Pairolero MD Kenneth J. Cherry MD | 1992 | Annals of Vascular Surgery1992，，1： | 1 |
| 6 | Who participates and why? An analysis of citizens on the internet and the mass public 显示文摘 | Lori M Weber Alysha Loumakis James Bergman | 2003 | Social Science Computer Review2003，，1： | 1 |
| 7 | 胆固醇酯转运蛋白抑制剂anacetrapib对血脂异常患者脂蛋白及健康个体24h动态血压的影响:2项双盲、随机、安慰剂对照Ⅰ期研究显示文摘背景抑制胆固醇酯转运蛋白(CETP)被认为有望成为治疗血脂异常的一种新策略。Anacetrapib(MK-0859)是目前正在研发的一种CETP抑制剂。本研究旨在评估anacetrapib作为单一治疗对低密度脂蛋白胆固醇(LDL—C)和高密度脂蛋白胆固醇(HDL-C)以及24h动态血压的影响。
方法作者进行了两项双盲、随机、安慰剂对照Ⅰ期研究。第一项研究中,50例年龄18~75岁的血脂异常患者(LDL—C1000~1900mg/L;治疗组40例,安慰剂组10例)接受anacetrapib治疗,剂量分别为每日餐后口服0mg、10mg、40mg、150mg或300mg,连续28d。采用标准的脂质和脂蛋白监测以及安全性监测,同时测定anacetrapib浓度进行药代动力学分析。第二项研究中,22例年龄为45~75岁的健康受试者接受每日餐后口服anacetrapib150mg或等量安慰剂治疗,连续10d,然后随机交换接受另一种治疗方法,各治疗期之间至少有14d洗脱期。研究过程中,每个治疗期的前1天和第10天进行24h动态血压监测。通过监测临床不良反应、体格检查、生命体征、12导联心电图和实验室安全性来评估两项研究安全性和耐受性的主要终点或次要终点。统计分析方法的选择符合方案分析。这两项试验均在ClinicalTrials.gov进行了注册,注册号分别为NCT00565292和NCT00565006。
结果血脂异常研究中,1例患者撤回知情同意书,1例因没有完整的服药前测定结果而在分析HDL—C和LDL—C数据时被剔除。Anacetrapib具有剂量依赖性调脂作用,对血脂异常患者其最大调脂作用为HDL—C增加129%[x=511(s=38)~x=1149(s=79)mg/L],而LDL-C降低38%[x=1382(s=114)~x=776(s=79)mg/L]。健康个体24h动态血压研究中,第10天时anacetrapib组和安慰剂组之间的最小方差为收缩压0.60mmHg(1mmHg≈0.133kPa)(90%CI-1.54~2.74;P=0.634),舒张压0.47mmHg(90%CI-0.90~1.84;P=0.561)。
结论Anacetrapib升高HDL-C的作用似乎远大于其他同类试验药物,而降低LDL-C的作用似乎与他汀类药物相似。尽管调脂作用强于其他同类药物,但anacetrapib似乎并不升高血压,这提示有效抑制CETP本身并不会使血压升高。 | Rajesh Krishna Matt S Anderson Arthur J Bergman Bo Jin Marissa Fallon Josee Cote Kim Rosko Cynthia Chavez-Eng Ryan Lutz Daniel MBloomfi eld Maria Gutierrez James Doherty Fredrick Bieberdorf Jeffrey Chodakewitz Keith M Gottesdiener John A Wagner 王亭忠(译) | 2008 | 世界临床医学2008，2，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员